Merck Serono Japan Launches Colon Cancer Drug Erbitux
This article was originally published in PharmAsia News
Merck KGaA Japanese subsidiary Merck Serono Japan launched colon cancer drug Erbitux (cetuximab) Sept. 19. The company is marketing the drug under a joint promotion agreement with Bristol-Myers Squibb. The drug is indicated to treat progressive and relapsing colon cancers. As Japanese diets are increasingly westernized, colon cancers cases are on the rise. (Click here for more - Japanese language
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.